Subject:
- Active Substance: Faricimab
- Name: Vabysmo®
- Therapeutic area: Neovascular age-related macular degeneration (nAMD)
- Pharmaceutical company: Roche Pharma AG
Time table:
- Start: 15.10.2022
- Final decision by G-BA: 06.04.2023
Final decision:
- No additional benefit proved